Exposure-response analyses of liraglutide 3.0 mg for weight management.

ABSTRACT:

Aims

Liraglutide 3.0 mg, an acylated GLP-1 analogue approved for weight management, lowers body weight through decreased energy intake. We conducted exposure-response analyses to provide important information on individual responses to given drug doses, reflecting inter-individual variations in drug metabolism, absorption and excretion.

Methods

We report efficacy and safety responses across a wide range of exposure levels, using data from one phase II (liraglutide doses 1.2, 1.8, 2.4 and 3.0 mg), and two phase IIIa [SCALE Obesity and Prediabetes (3.0 mg); SCALE Diabetes (1.8; 3.0 mg)] randomized, placebo-controlled trials (n = 4372).

Results

There was a clear exposure-weight loss response. Weight loss increased with greater exposure and appeared to level off at the hi

SUBMITTER: Wilding JP 

PROVIDER: S-EPMC5069568 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature